 |
 |
|
|
| |
|
|
|
Glucosamine:
A Review of the Literature
|
- The Discovery Period (1956 1978)
- 1956 The first major paper entitled "Effect of Hexosamines on the Synthesis of Chondroitin sulphuric acid in vitro" by Lennart Roden of the Karolinska Institute (Stockholm, Sweden) was published in Arkiv for Kemi (Band 10 nr 23).
This benchmark work involved Glucosamine HCl and Galactosamine HCl and showed that Glucosamine HCl stimulated production of Chondroitin Sulfate in slices of cartilage by as much as 250 to 320% of the control value. Under identical circumstances, Galactosamine only stimulated production of chondroitin sulfate by only twice the control value.
- 1971 The second significant paper entitled "Effects of Hexosamine Derivatives and Uronic Acid Derivatives on Glycosaminoglycane Metabolism of Fibroblast Cultures" by Karzel et al at the Institute of Pharmacology, University of Bonn was published In Pharmacology 5: 337-345 (1971).
Karzel studied the effects of Glucosamine HCl, Glucosamine Iodide and Glucosamine Sulfate on the secretion of mucopolysaccharide (aka glycosaminoglycan) of murine embryonic fibroblast monolayer cultures. This work showed clearly that glucosamine and the glucosamine derivatives (Glucosamine HCl, Glucosamine Iodide and Glucosamine Sulfate) are capable of enhancing the release and probably the production of mucopolysaccharides by fibroblasts in vitro. The data further shows that, on a weight to weight basis, Glucosamine HCl seems to possess a somewhat stronger effect then either Glucosamine Sulfate or Glucosamine Iodide. However, when the results are calculated with reference to the molecular weights of the three compounds, no difference is demonstrable.
- 1974 The third paper of interest entitled "Effect of D-Glucosamine Concentration on the Kinetics of Mucopolysaccharide Biosynthesis in Cultured Chick Embryo Vertebral Cartilage" by Kim & Conrad (Dept. of Biochemistry, University of Illinois, Urbana, IL) was published in The Journal of Biological Chemistry (Vol. 249, No. 10, Issue of May 25, pp. 3091-3097, 1974).
The work utilizes C14-tagged Glucosamine HCl and C14-tagged Galactosamine HCl and measures the effect of both on the rate of chondroitin sulfate synthesis in the specified cultures. Kim was able to show that the tagged glucosamine hydrochloride not only has a pronounced effect on hyaluronic acid and chondroitin sulfate synthesis but is incorporated into chondroitin sulfate at 10 times the rate of the tagged galactosamine. No sulfur source was added to any of the cultures tested.
(NOTE: Hyaluronic Acid consists of repetitive units of glucosamine-uronic acid while chondroitin sulfate consists of repetitive units of galactosamine-uronic acid. Glucosamine is incorporated into chondroitin sulfate only after conversion from glucosamine to galactosamine during biosynthesis)
- 1978 - The fourth paper entitled "Articular Cartilage Pharmacology: I. InVitro Studies on Glucosamine and Non Steroidal Anti-inflammatory Drugs" by Plana et al (Rotta Research Laboratories S.p.A, Milan, Italy) was published in Pharmacological Research Communications, Vol. 10, No. 6, 1978.
Plana worked exclusively with Glucosamine HCl and was able to show that Glucosamine HCl stimulates in a dose dependent manner soluble mucopolysaccharide release by "in vitro" cultured mouse fibroblasts. According to Plana, these results are in agreement with those reported by Karzel. He was also able to demonstrate agreement with Kims earlier work. Plana further showed that the dose-dependent enhancing activity of Glucosamine HCl not only contrasted to the dose-dependent depressing activity of non-steroidal anti-inflammatory drugs but also could diminish in a statistically significant way the depressing activity of the NSAID on protein and mucopolysaccharide synthesis.
- The Clinicals
- In 1980, two years after Planas work on Glucosamine HCl, Rotta Research Laboratories began sponsoring a series of clinical trials utilizing Glucosamine Sulfate as the preferred therapeutic drug for osteoarthritis. The objective of these trials was to achieve drug status in the European pharmaceutical marketplace. Why the sulfate form after taking such care to confirm the early in vitro studies? Rotta claims that the sulfate from the glucosamine is beneficial but does not offer any science to support this contention. In fact, the published work shows no preference for the sulfate over the hydrochloride.
- Real World Economics: Like almost all pharmaceutical companies, money is spent on new drugs only if the sponsor can protect their investment. Rotta was able to protect their investment by acquiring the rights to an existing production patent (US Patent 3,683,076 issued in 1972 to Luigi Rovati, no assignment) on the sulfate form and hiring the inventor Luigi Rovati. This was followed in 1987 by a second production method patent (US Patent 4,642,340 issued to Luigi Rovati et al and assigned to Rotta). No such protection was available on Glucosamine HCl. In fact, it is the difficulty of making a stable Glucosamine Sulfate that presented the patent opportunity. Glucosamine HCl is relatively easy to make and very stable.
- Proof Positive: The Pharmacokinetics of Glucosamine
- In 1986 and 1993, Rotta Research published pharmacokinetic data on Glucosamine Sulfate in both dog and man. Close examination of this work shows the following:
- The tagged glucosamine used in the testing was C14-tagged glucosamine hydrochloride, which was subsequently mixed with untagged glucosamine sulfate. The results, which are reported as glucosamine sulfate, should be reported as glucosamine hydrochloride.
- The 1986 study also sheds light on what happens to orally administered glucosamine sulfate. Under paragraph 4.1 entitled "Physical properties of glucosamine" the authors establish that glucosamine has a pKa of 6.91 at 37 degrees C and state that orally consumed glucosamine is 100% ionized in stomach acid (pH 1-3). This means that glucosamine sulfate exists in the stomach as free glucosamine ions and sulfate ions in a vast sea of Chloride ions from the gastric (hydrochloric) acid. As the stomach contents move to the small intestine, the pH rises to approximately 6.8 and glucosamine now is 46% ionized and 54% not ionized. It is also not glucosamine sulfate. If any salt reforms, it will be the hydrochloride due to the overwhelming preponderance of chloride from the stomach acid. In fact, the "not ionized" portion is the neutral aminosugar glucosamine. This is fortunate because neutral compounds move through cell walls much more readily than do charged ions. Thus, neutral glucosamine moves from the small intestine into the blood stream where, at a pH of 7.4, 25% of the glucosamine is ionized and 75% is not ionized.
- Fact from Fiction
- Based on the preceding, there is no valid science to claim that glucosamine sulfate is more readily absorbed from the gut than is glucosamine hydrochloride. What is absorbed in either case is glucosamine the salt is irrelevant.
- As to the claim that the sulfate ion from the glucosamine is important to subsequent formation of sulfated mucopolysaccharides like chondroitin sulfate also has no basis in science. Sulfate ions are eliminated as waste products. The sulfur used in the synthesis of sulfated mucopolysaccharides comes from the protein sulfur linkages as old collagen breakdowns. If you want to supplement bioavailable sulfur, you would need to consume products like methionine and MSM (methysulfonylmethane) or just good old protein.
- The active ingredient in the treatment of osteoarthritis is glucosamine. Like many other drugs, the hydrochloride or sulfate acid salt is the delivery vehicle. Once it has entered the stomach, the salts job is done and it is the glucosamine that is released to perform its function.
- Summary Comparison
- The following table shows the differences between Glucosamine HCl and commercially available Glucosamine Sulfate 2KCl (Glucosamine Sulfate is cocrystallized with 2 moles of potassium chloride or sodium chloride in order to maintain stability):
Comparative Attribute |
Glucosamine HC |
Glucosamine Sulfate2KC |
Purity (as the acid salt) |
99+% |
75% (25% KCl) |
Weight % as Glucosamine |
83.1% |
59.5% |
Dosage Delivery Equivalents: |
|
|
1,500 mg Glucosamine |
1,805 mg tot. weight |
2,521 mg tot. weight |
Manufacturing Source |
US Plant-cGMP/DMF
China-
None /None
|
China -
No cGMP/No DMF
Italy / ? /No
Other US/ ? /No
|
|
|
|
|
 |
| Call Toll Free 800.350.7017 Privacy Policy | Returns | Shipping | Terms & Conditions | Contact Us |
This website and these statements have not been evaluated by the Food and Drug Administration.
These products are not intended to diagnose, treat, cure, or prevent any disease. Please consult a properly trained medical practitioner for medical advice.
All Material at this site Copyright © 2007 NutraSense™ All Rights Reserved. |
|
 |
|